|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400089463 |
|
最近更新日期: Date of Last Refreshed on: |
2024-09-09 16:47:59 |
|
注册时间: Date of Registration: |
2024-09-09 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于人工智能算法的糖尿病前期患者慢性肾脏病风险预测模型的构建和验证研究 |
|
Public title: |
Research on the construction and validation of a risk prediction model for chronic kidney disease in prediabetic patients based on artificial intelligence algorithms |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于人工智能算法的糖尿病前期患者慢性肾脏病风险预测模型的构建和验证研究 |
|
Scientific title: |
Research on the construction and validation of a risk prediction model for chronic kidney disease in prediabetic patients based on artificial intelligence algorithms |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杨华 |
研究负责人: |
杨华 |
|
Applicant: |
Hua Yang |
Study leader: |
Hua Yang |
|
申请注册联系人电话: Applicant telephone: |
+86 13918220239 |
研究负责人电话:
Study leader's |
+86 21 64041990 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yang.hua@zs-hospital.sh.cn |
研究负责人电子邮件: Study leader's E-mail: |
yang.hua@zs-hospital.sh.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市枫林路180号 |
研究负责人通讯地址: |
枫林路180号五号楼509室 |
|
Applicant address: |
180 Fenglin Road, Shanghai, China |
Study leader's address: |
Room 509,Building 5#.No.180 Fenglin Road ,Xuhui District,Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
复旦大学附属中山医院 |
||
|
Applicant's institution: |
Zhongshan Hospital,Fudan University |
||
|
研究负责人所在单位: |
复旦大学附属中山医院 |
||
|
Affiliation of the Leader: |
Zhongshan Hospital, Fudan University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
B2024-188R |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
复旦大学附属中山医院医学伦理委员会分委会一 |
||
|
Name of the ethic committee: |
Ethics Committee of Zhongshan Hospital Fudan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-12 00:00:00 | ||
|
伦理委员会联系人: |
杨梦婕 |
||
|
Contact Name of the ethic committee: |
Yang MengJie |
||
|
伦理委员会联系地址: |
枫林路180号五号楼509室 |
||
|
Contact Address of the ethic committee: |
Room 509,Building 5#.No.180 Fenglin Road ,Xuhui District,Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 31587871 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
yang.mengjie@zs-hospital.sh.cn |
|
研究实施负责(组长)单位: |
复旦大学附属中山医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Zhongshan Hospital, Fudan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
枫林路180号五号楼509室 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Room 509,Building 5#.No.180 Fenglin Road ,Xuhui District,Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
上海市卫生健康委员会卫生行业临床研究专项 |
||||||||||||||||||||||
|
Source(s) of funding: |
Shanghai Municipal Health Commission Health Industry Clinical Research Project |
||||||||||||||||||||||
|
研究疾病: |
糖尿病前期 |
||||||||||||||||||||||
|
Target disease: |
Prediabetes |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
构建糖尿病前期患者的慢性肾脏病风险预测模型 |
||||||||||||||||||||||
|
Objectives of Study: |
To construct a risk prediction model of chronic kidney disease in prediabetic patients |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.① 符合《中国 2 型糖尿病防治指南(2020 年版)》中 IFG 或 IGT 或 IFG+IGT 诊断标准。 ② 年龄≥18 岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1.① Meet the IFG or IGT or in the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition) IFG+IGT diagnostic criteria. ②Age ≥18 years old; |
||||||||||||||||||||||
|
排除标准: |
1.①既往临床已确诊有肾小球肾炎、肾小管间质性疾病、肾血管性疾病、代 谢性疾病和结缔组织疾病性肾损害、感染性肾损害、先天性和遗传性肾脏疾病 和肾移植病史,或肾活检提示有慢性肾脏病史者。 ②妊娠者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.① Previous clinical diagnosis of glomerulonephritis, renal tubulointerstitial disease, renal vascular disease, generation Kidney damage due to kidney disease and connective tissue disease, infectious kidney damage, congenital and hereditary kidney diseases And a history of kidney transplantation, or a kidney biopsy suggesting a history of chronic kidney disease. ② Pregnant persons. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-01 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-10-01 00:00:00 至 To 2026-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not shared |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
训练集数据来源于复旦大学附属中山医院大数据平台;验证集数据来源于复旦大学附属中山医院(厦门)大数据平台;测试集数据来源于上海市数家社卫生卫生中心的电子病历系统、中国慢性病前瞻性研究(CKB)数据库和 美国人群营养横断面调查(NHANES)数据库。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The data of the training set came from the big data platform of Zhongshan Hospital Affiliated to Fudan University. Validation set data came from big data platform of Zhongshan Hospital Affiliated to Fudan University (Xiamen); The data of the test set were collected from the electronic medical record system of several community health centers in Shanghai, the Chinese Prospective Study of Chronic Diseases (CKB) database, and the database National Population Nutrition Cross-Sectional Survey (NHANES) database. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |